A Study of REGN5093 in Adult Patients With Mesenchymal Epithelial Transition Factor (MET)-Altered Advanced Non-Small Cell Lung Cancer

This study will evaluate REGN5093 for the treatment of Non-Small Cell Lung Cancer (NSCLC) with MET alteration. The main purpose of this study is to determine the safety, tolerability, and effectiveness of REGN5093. The study has two phases. The main goal of Phase 1 is to determine a safe dose(s) of REGN5093. The main goal of phase 2 of the study is to use the REGN5093 drug dose(s) found in Phase 1 to see how well REGN5093 works to shrink tumors. The study is looking at several other research questions, including: * Side effects that may be experienced by people taking REGN5093 * How REGN509

Trial Details

NCT ID

NCT04077099

Phase

PHASE1 / PHASE2

Sponsor

Regeneron Pharmaceuticals

Status

RECRUITING

Cancer Type

Lung Cancer

Interventions

REGN5093

Locations (sample)

Birmingham, Alabama, United States|33.52066,-86.80249
Orange, California, United States|33.78779,-117.85311
Washington D.C., District of Columbia, United States|38.89511,-77.03637
Tampa, Florida, United States|27.94752,-82.45843
Lexington, Kentucky, United States|37.98869,-84.47772

Key Eligibility Criteria

Histologically confirmed advanced NSCLC that is unresectable or metastatic as described in the protocol
Willing to provide tumor tissue as described in the protocol
Documented presence of MET alteration as described in the protocol.
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →